Neodymium:YAG laser hysteroscopy in large submucous fibroids

Donnez, Jacques; Gillerot, Stéphane; Bourgonjon, Damien; Clerckx, Françoise; Nisolle, Michelle

doi:10.1016/s0015-0282(16)53994-6

Cited by 164 publications

(88 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…All patients were observed overnight and discharged from the hospital on the fi rst post-operative day. Myolysis as a treatment option for uterine myomas was fi rst introduced in the late 1980s as a hysteroscopic technique [14]. Subsequently, myolysis was performed as a variation on the technique of laparoscopic myomectomy in which myomas are coagulated rather than removed.…”

Section: Discussionmentioning

confidence: 99%

Study on the changes in sexual functioning and clinical symptoms before and after radiofrequency myolysis in women with uterine myoma

Choi

Kim

et al. 2011

Korean J Obstet Gynecol

View full text Add to dashboard Cite

ObjectiveThe purpose of this study was to estimate sexual functioning and clinical symptoms after radiofrequency (RF) myolysis of uterine myomas. MethodsFifty-four patients who had undergone RF myolysis in the Department of Obstetrics and Gynecology at Chosun University Hospital were surveyed regarding changes in the number, diameter, volume of myomas, sexual functioning and clinical symptoms before and 6 months after the procedure. ResultsThe mean age of the patients was 43 ± 4.048 years. The following clinical symptoms (dysmenorrhea, menorrhagia, abdominal pain, dyspareunia, pelvic pressure, back pain, urinary frequency and leg pain) were improved signifi cantly 6 months after RF myolysis (P < 0.001). The results following parameters of sexual function (desire for sex, frequency of sex, frequency of orgasm and strength of orgasm) were no signifi cant differences before and after RF myolysis. The diameter and volume of myomas were signifi cantly reduced 6 months after than before RF myolysis (P < 0.05). ConclusionRF myolysis is effective in improvement of clinical symptoms without an infl uence on sexual functioning and reduction of myoma size.

show abstract

Section: Discussionmentioning

confidence: 99%

Study on the changes in sexual functioning and clinical symptoms before and after radiofrequency myolysis in women with uterine myoma

Choi

Kim

et al. 2011

Korean J Obstet Gynecol

View full text Add to dashboard Cite

show abstract

“…We did not give gonadotropin releasing hormone agonist therapy to any of our patients prior to resection. In Donnez [9] series of 24 women who wished to become pregnant and had no other infertility factors, 66% became pregnant. However, in our series pregnancy rate was only 25%.…”

Section: Discussionmentioning

confidence: 99%

Fertility Enhancing Hysteroscopic Surgery: Our Experience

Duggal

Sharma

Tarneja

et al. 2003

Medical Journal Armed Forces India

View full text Add to dashboard Cite

“…It has been postulated that by reducing fibroid volume the operating time is reduced, thereby lowering the risk of excessive fluid absorption and overload [21]. Interestingly, it has been suggested that reduction in fibroid size induced by preoperative GnRHa also results in a higher proportion of the tumour protruding into the endometrial cavity, increasing the chance of complete resection of the sub mucous fibroid [21][22][23]. Despite these theoretical advantages, until recently there had been no randomized clinical trials comparing TCRF with or without GnRHa pre-treatment.…”

Section: There Is Conflicting Evidence For the Benefits Of Gnrha Usedmentioning

confidence: 99%

GnRH Agonists: Do They Have a Place in the Modern Management of Fibroid Disease?

Talaulikar

Belli

Manyonda

2012

J Obstet Gynecol India

View full text Add to dashboard Cite

In the management of women with fibroid disease, GnRH agonists (GnRHa) are frequently used to reduce volume and vascularity before myomectomy, apparently to render the operation easier and reduce operative blood loss, and to enable a transverse supra-pubic incision instead of a midline vertical one. They induce amenorrhoea and thus aid in the correction of pre-operative anaemia. Other gynaecologists use GnRHa to shrink sub mucous fibroids greater than 5 cm in diameter to facilitate access and reduce blood loss and operating time at transcervical resection. GnRHa are also occasionally used as a temporizing measure in women with symptomatic fibroids within the climacteric. We argue against the use of GnRHa in the management of fibroid disease because they are not cost effective, render myomectomy more difficult to apply because they destroy tissue planes, the more difficult enucleation in fact increasing rather than reducing perioperative blood loss and operating time. When used before myomectomy, they increase the risk of 'recurrence' because they obscure smaller fibroids that 'recur' when the effects of the GnRHa wear off, and are associated with side effects in situations where they confer no benefits, or where alternative cheaper drugs with fewer side effects are available.

show abstract

Neodymium:YAG laser hysteroscopy in large submucous fibroids

Cited by 164 publications

References 5 publications

Study on the changes in sexual functioning and clinical symptoms before and after radiofrequency myolysis in women with uterine myoma

Study on the changes in sexual functioning and clinical symptoms before and after radiofrequency myolysis in women with uterine myoma

Fertility Enhancing Hysteroscopic Surgery: Our Experience

GnRH Agonists: Do They Have a Place in the Modern Management of Fibroid Disease?

Contact Info

Product

Resources

About